Hong‐Min Ni, Abigail Bockus, Nikki Boggess, Hartmut Jaeschke, Wen‐Xing Ding – 19 September 2011 – Autophagy can selectively remove damaged organelles, including mitochondria, and, in turn, protect against mitochondria‐damage–induced cell death. Acetaminophen (APAP) overdose can cause liver injury in animals and humans by inducing mitochondria damage and subsequent necrosis in hepatocytes. Although many detrimental mechanisms have been reported to be responsible for APAP‐induced hepatotoxicity, it is not known whether APAP can modulate autophagy to regulate hepatotoxicity in hepatocytes.

José M. Mato, Shelly C. Lu – 6 September 2011

Asunción Moreno, Carlos Cervera, Jesús Fortún, Marino Blanes, Estibalitz Montejo, Manuel Abradelo, Oscar Len, Antonio Rafecas, Pilar Martín‐Davila, Julián Torre‐Cisneros, Magdalena Salcedo, Elisa Cordero, Ricardo Lozano, Iñaki Pérez, Antonio Rimola, José M. Miró, the OLT‐HIV FIPSE Cohort Investigators – 6 September 2011 – Information about infections unrelated to acquired immunodeficiency syndrome (AIDS) in human immunodeficiency virus (HIV)–infected liver recipients is scarce.

Yun Young Lee, Geum‐Youn Gwak, Kwang Hyuck Lee, Jong Kyun Lee, Kyu Taek Lee, Choon Hyuck David Kwon, Jae‐Won Joh, Suk‐Koo Lee – 6 September 2011 – Biliary strictures are a major cause of morbidity and mortality for liver transplant recipients. The endoscopic management of biliary strictures is not well established after living donor liver transplantation (LDLT) in comparison with deceased donor liver transplantation.

Natasha K. Martin, Peter Vickerman, Alec Miners, Graham R. Foster, Sharon J. Hutchinson, David J. Goldberg, Matthew Hickman – 2 September 2011 – Injecting drug use is the main risk of hepatitis C virus (HCV) transmission in most developed countries. HCV antiviral treatment (peginterferon‐α + ribavirin) has been shown to be cost‐effective for patients with no reinfection risk. We examined the cost‐effectiveness of providing antiviral treatment for injecting drug users (IDUs) as compared with treating ex/non‐IDUs or no treatment.

Diego M. Avella, Guangfu Li, Todd D. Schell, Dai Liu, Samuel Shao‐Min Zhang, Xi Lou, Arthur Berg, Eric T. Kimchi, Hephzibah Rani S. Tagaram, Qing Yang, Serene Shereef, Luis S. Garcia, Mark Kester, Harriet C. Isom, C. Bart Rountree, Kevin F. Staveley‐O'Carroll – 2 September 2011 – The high rate of mortality and frequent incidence of recurrence associated with hepatocellular carcinoma (HCC) reveal the need for new therapeutic approaches.

Seyed Mohamad Jazayeri, Seyed Moayed Alavian – 2 September 2011

Florian Baumgartner, Andreas Villunger – 2 September 2011

Anna Dittrich, Christina Khouri, Sara Dutton Sackett, Christian Ehlting, Oliver Böhmer, Ute Albrecht, Johannes G. Bode, Christian Trautwein, Fred Schaper – 2 September 2011 – Glucocorticoids are known to be potent regulators of inflammation and have been used pharmacologically against inflammatory, immune, and lymphoproliferative diseases for more than 50 years. Due to their possible and well‐documented side effects, it is crucial to understand the molecular mechanisms and targets of glucocorticoid action in detail.

Jérôme Boursier, Victor de Ledinghen, Jean‐Pierre Zarski, Isabelle Fouchard‐Hubert, Yves Gallois, Frédéric Oberti, Paul Calès, multicentric groups from SNIFF 32, VINDIAG 7, and ANRS/HC/EP23 FIBROSTAR studies – 2 September 2011 – The sequential algorithm for fibrosis evaluation (SAFE) and the Bordeaux algorithm (BA), which cross‐check FibroTest with the aspartate aminotransferase‐to‐platelet ratio index (APRI) or FibroScan, are very accurate but provide only a binary diagnosis of significant fibrosis (SAFE or BA for Metavir F ≥ 2) or cirrhosis (SAFE or BA for F4).